Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Aug;111(8):1406-15.
doi: 10.1111/add.13363. Epub 2016 Apr 21.

A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults

Lisa A Marsch  1 , Sarah K Moore  2 , Jacob T Borodovsky  1 , Ramon Solhkhah  3 , Gary J Badger  4 , Shelby Semino  5 , Kate Jarrett  6 , Kathleen DiGangi Condon  7 , Kate Rossettie  8 , Phillip Vincent  3 , Neda Hajizadeh  6 , Elizabeth Ducat  9
Affiliations
Randomized Controlled Trial

A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults

Lisa A Marsch et al. Addiction. 2016 Aug.

Abstract

Background and aims: Few randomized controlled trials have evaluated buprenorphine treatment interventions for opioid-dependent youth. Consequently, optimal administration strategies for this cohort are unclear. Our aim was to evaluate the relative efficacy of two different buprenorphine taper lengths in promoting abstinence from illicit opioids and treatment retention among opioid-dependent youth.

Design: A double-blind, placebo controlled, multicenter randomized controlled trial.

Setting: Two hospital-based research clinics (Manhattan and Brooklyn) in New York City, USA from 2005 to 2010.

Participants: Volunteer sample of 53 primarily Caucasian participants between the ages of 16 and 24 (n = 11 under age 18) who met DSM-IV opioid dependence criteria.

Intervention: Participants were assigned randomly to either a 28-day buprenorphine taper (n = 28) or 56-day buprenorphine taper (n = 25) via a parallel-groups design during a 63-day period. Both groups received behavioral counseling and opioid abstinence incentives. Both taper conditions had a minimum of 1 week of placebo dosing at the end of the taper.

Measurements: The primary outcome was opioid abstinence measured as a percentage of scheduled urine toxicology tests documented to be negative for opioids. The secondary outcome was treatment retention, measured as number of days attended scheduled visits.

Findings: Intent-to-treat analyses revealed that participants who received a 56-day buprenorphine taper had a significantly higher percentage of opioid-negative scheduled urine tests compared with participants who received a 28-day buprenorphine taper [35 versus 17%, P = 0.039; Cohen's d = 0.57, 95% confidence interval (CI) = 0.02, 1.13]. Participants who received a 56-day buprenorphine taper were retained in treatment significantly longer than participants who received a 28-day buprenorphine taper (37.5 versus 26.4 days, P = 0.027; Cohen's d = 0.63, 95% CI = 0.06, 1.19). Daily attendance requirement was associated with decreased abstinence and shorter retention compared with a two to three times weekly attendance requirement, independent of taper duration. Follow-up data were insufficient to report.

Conclusion: Longer (56-day) buprenorphine taper produces better opioid abstinence and retention outcomes than shorter (28-day) buprenorphine taper for opioid-dependent youth.

Trial registration: ClinicalTrials.gov NCT00182572.

Keywords: Adolescent; Young adult; buprenorphine; detoxification; opioid use disorder; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CONSORT Diagram
Figure 2
Figure 2
Mean Percent of Urine Screens Documented as Opioid Negative by Buprenorphine Treatment Condition Before and After Changes in Attendance Requirement
Figure 3
Figure 3
Retention by Buprenorphine Treatment Condition Before and After Changes in Attendance Requirement
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lifestyles Statistics Health and Social Care Information Centre Statistics on Drug Misuse England 2014. 2014:1.
    1. United Nations Office on Drugs and Crime Organization WH, editor. Opioid overdose: preventing and reducing opioid overdose mortality. 2013
    1. United Nations Office on Drugs and Crime . World Drug Report. United Nations publication; 2015. Sales No E15XI6.
    1. Center for Behavioral Health Statistics and Quality Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health. 2015
    1. Johnston LD, O'Malley PM, Miech RA, Bachman JG, Schulenberg JE. Monitoring the Future national results on drug use: 1975-2014: Overview, Key Findings on Adolescent Drug Use. Institute for Social Research, The University of Michigan; Ann Arbor: 2015.

Publication types

Associated data